Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability of oral imatinib using an intravenous imatinib-d8 microdose
NL-OMON21434Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of imatinib in cancer and gastrointestinal stromal tumor (GIST), sponsored by Netherlands Cancer Institute. Primary endpoint: Absolute bioavailability of oral imatinib at steady state. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
03
Conditions
cancergastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON21434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21434.